Bharat Biotech Initiates MTBVAC Tuberculosis Vaccine Clinical Trials In India

The Bharat Biotech clinical on Sunday Expressed trials for the novel tuberculosis (TB) vaccine MTBVAC in India mark a significant milestone in the global fight against one of the deadliest infectious diseases, claiming over 1.6 million lives annually worldwide. Developed through a collaborative effort between Biofabri and Bharat Biotech, MTBVAC represents a promising advancement in TB prevention and treatment.

Derived from a human strain of the Mycobacterium tuberculosis bacterium, MTBVAC offers a more effective and enduring alternative to the century-old BCG vaccine, which provides limited protection against pulmonary TB, the most prevalent and contagious type of the illness.

The commencement of clinical trials in India underscores the country's crucial role in combating TB, given its status as the nation with the highest burden of TB globally. With more than 10 million infections reported worldwide each year, the urgent need for an enhanced defense against TB cannot be overstated.

The primary objectives of these clinical trials are to evaluate MTBVAC's safety, immunogenicity, and efficacy. After over three decades of dedicated research, MTBVAC has entered a pivotal phase of assessment. Phase 3 clinical trials in newborns began in 2023, directly comparing MTBVAC's efficacy with that of the traditional BCG vaccine. Concurrently, trials involving both HIV-uninfected and HIV-infected adults have been initiated to assess safety and immunogenicity. Plans are also underway for further efficacy studies targeting adolescents and adults in Sub-Saharan Africa.

Esteban Rodriguez, CEO of Biofabri, emphasised the significance of testing MTBVAC in India, stating, "After more than three decades of research, it is a giant step to test in adults and adolescents in the country where 28 percent of the world's TB cases accumulate." Rodriguez stressed the ongoing need for increased efforts and funding to effectively combat TB, recognising it as one of the leading infectious causes of death globally, particularly in India.

Krishna Ella, Executive Chairman of Bharat Biotech, expressed optimism about the potential impact of MTBVAC in preventing TB among adults and adolescents, stating, "Our quest for a more effective vaccine against tuberculosis received a big boost today, with clinical trials in India." He underscored the significance of the partnership with BioFabri and hailed the commencement of clinical trials as a substantial step forward in their mission to develop TB vaccines.

MTBVAC's development is a testament to the power of global collaboration. Through a public-private partnership, various entities, including the European Union, American institutions like the International AIDS Vaccine Initiative (IAVI), and the National Institutes of Health, have contributed to funding and conducting different stages of the trials. This collaborative effort highlights the shared commitment to addressing the global TB crisis and underscores the importance of collective action in combating infectious diseases.

As the clinical trials progress, researchers will closely monitor MTBVAC's safety profile, its ability to elicit an immune response, and its efficacy in preventing TB in diverse populations. Success in these endeavours could herald a new era in TB prevention, offering hope to millions worldwide who are at risk of contracting this devastating disease.

The initiation of clinical trials for MTBVAC in India represents a significant step forward in the fight against tuberculosis. With its potential to provide superior protection compared to existing vaccines, MTBVAC offers hope in the quest to eradicate TB as a global health threat. As research advances and collaborations continue, the prospect of a TB-free world becomes increasingly attainable, promising a brighter future for generations to come.